National Cancer Institute LAO clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 0 with minor changes only.

1. Notable

   Ipilimumab and Nivolumab Combination With or Without Cabozantinib…Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

   Primary and study completion pushed from May 15, 2026 to May 15, 2028

   National Cancer Institute LAO·Phase 2· NCT05836571· Registry history of NCT05836571 on ClinicalTrials.gov (opens the registry)

   Updated Oct 9, 2026

2. Notable

   Collection and Storage of Tissue and Blood Samples From · Cancer

   Primary and study completion pushed from May 4, 2026 to May 4, 2028

   National Cancer Institute LAO·Not specified· NCT02474160· Registry history of NCT02474160 on ClinicalTrials.gov (opens the registry)

   Updated Oct 9, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.